TP53 and chronic myelogenous leukemia, BCR-ABL1 positive: Combining drug treatments in normal and CML LSCs in vitro with in vivo xenograft NSG and syngeneic SCLtTA/BCR-ABL transgenic models, the authors effectively used numerous preclinical models to illustrate that dual targeting of p53 and c-Myc in CML can synergistically kill and eliminate BCR-ABL+ LSCs through increased apoptosis and differentiation.